202 related articles for article (PubMed ID: 11551516)
21. Characterization of cytochrome P450 expression in human oesophageal mucosa.
Lechevrel M; Casson AG; Wolf CR; Hardie LJ; Flinterman MB; Montesano R; Wild CP
Carcinogenesis; 1999 Feb; 20(2):243-8. PubMed ID: 10069460
[TBL] [Abstract][Full Text] [Related]
22. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of procarcinogen-bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin.
Chang TK; Chen J; Yang G; Yeung EY
J Pineal Res; 2010 Jan; 48(1):55-64. PubMed ID: 19919601
[TBL] [Abstract][Full Text] [Related]
24. Effect of eurycomanone on cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 and CYP3A4 in vitro.
Pan Y; Tiong KH; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Ong CE
J Nat Med; 2014 Apr; 68(2):402-6. PubMed ID: 23881640
[TBL] [Abstract][Full Text] [Related]
25. Human cytochrome P450 isozymes in metabolism and health effects of gasoline ethers.
Hong JY; Wang YY; Mohr SN; Bondoc FY; Deng C
Res Rep Health Eff Inst; 2001 May; (102):7-27; discussion 95-109. PubMed ID: 11504148
[TBL] [Abstract][Full Text] [Related]
26. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA.
Jacobson PA; Green K; Birnbaum A; Remmel RP
Cancer Chemother Pharmacol; 2002 Jun; 49(6):461-7. PubMed ID: 12107550
[TBL] [Abstract][Full Text] [Related]
27. Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: role of CYP2C isoforms in human liver microsomes.
Hamitouche S; Poupon J; Dreano Y; Amet Y; Lucas D
Toxicol Lett; 2006 Dec; 167(3):221-30. PubMed ID: 17084997
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the dose-response of CYP1B1, CYP1A1, and CYP1A2 in the liver of female Sprague-Dawley rats following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Walker NJ; Portier CJ; Lax SF; Crofts FG; Li Y; Lucier GW; Sutter TR
Toxicol Appl Pharmacol; 1999 Feb; 154(3):279-86. PubMed ID: 9931287
[TBL] [Abstract][Full Text] [Related]
29. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes.
Qi XY; Liang SC; Ge GB; Liu Y; Dong PP; Zhang JW; Wang AX; Hou J; Zhu LL; Yang L; Tu CX
Food Chem Toxicol; 2013 Jun; 56():392-7. PubMed ID: 23500771
[TBL] [Abstract][Full Text] [Related]
31. Inhibition selectivity of grapefruit juice components on human cytochromes P450.
Tassaneeyakul W; Guo LQ; Fukuda K; Ohta T; Yamazoe Y
Arch Biochem Biophys; 2000 Jun; 378(2):356-63. PubMed ID: 10860553
[TBL] [Abstract][Full Text] [Related]
32. Cytochrome P450 species involved in the metabolism of quinoline.
Reigh G; McMahon H; Ishizaki M; Ohara T; Shimane K; Esumi Y; Green C; Tyson C; Ninomiya S
Carcinogenesis; 1996 Sep; 17(9):1989-96. PubMed ID: 8824525
[TBL] [Abstract][Full Text] [Related]
33. Effects of cigarette smoking and exposure to cadmium and lead on phenotypic variability of hepatic CYP2A6 and renal function biomarkers in men.
Satarug S; Ujjin P; Vanavanitkun Y; Nishijo M; Baker JR; Moore MR
Toxicology; 2004 Nov; 204(2-3):161-73. PubMed ID: 15388242
[TBL] [Abstract][Full Text] [Related]
34. Halothane-dependent lipid peroxidation in human liver microsomes is catalyzed by cytochrome P4502A6 (CYP2A6).
Minoda Y; Kharasch ED
Anesthesiology; 2001 Aug; 95(2):509-14. PubMed ID: 11506127
[TBL] [Abstract][Full Text] [Related]
35. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.
Polasek TM; Elliot DJ; Somogyi AA; Gillam EM; Lewis BC; Miners JO
Br J Clin Pharmacol; 2006 May; 61(5):570-84. PubMed ID: 16669850
[TBL] [Abstract][Full Text] [Related]
36. Induction of liver microsomal cytochrome P450 in cynomolgus monkeys.
Bullock P; Pearce R; Draper A; Podval J; Bracken W; Veltman J; Thomas P; Parkinson A
Drug Metab Dispos; 1995 Jul; 23(7):736-48. PubMed ID: 7587963
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma.
Mochizuki J; Murakami S; Sanjo A; Takagi I; Akizuki S; Ohnishi A
J Gastroenterol Hepatol; 2005 Aug; 20(8):1191-7. PubMed ID: 16048566
[TBL] [Abstract][Full Text] [Related]
38. In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide).
Bournique B; Lambert N; Boukaiba R; Martinet M
Br J Clin Pharmacol; 2001 Jul; 52(1):53-63. PubMed ID: 11453890
[TBL] [Abstract][Full Text] [Related]
39. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.
Messina ES; Tyndale RF; Sellers EM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1608-14. PubMed ID: 9316878
[TBL] [Abstract][Full Text] [Related]
40. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes.
Madan A; Graham RA; Carroll KM; Mudra DR; Burton LA; Krueger LA; Downey AD; Czerwinski M; Forster J; Ribadeneira MD; Gan LS; LeCluyse EL; Zech K; Robertson P; Koch P; Antonian L; Wagner G; Yu L; Parkinson A
Drug Metab Dispos; 2003 Apr; 31(4):421-31. PubMed ID: 12642468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
